"Dr Califf also consults for TheHeart.org, Johnson & Johnson, Scios, Kowa Research Institute, Nile, Parkview, Orexigen Therapeutics, Pozen, WebMD, Bristol-Myers Squibb Foundation, AstraZeneca, Bayer/Ortho-McNeil, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Gilead, GlaxoSmithKline, Li Ka Shing Knowledge Institute, Medtronic, Merck, Novartis, sanofi-aventis, XOMA, University of Florida, Pfizer, Roche, Servier International, DSI-Lilly, Janssen R&D, CV Sight, Regeneron, and Gambro; all income from these consultancies is donated to nonprofit organizations, with most going to the clinical research fellowship fund of the Duke Clinical Research Institute, Dr Califf holds equity in Nitrox LLC, N30 Pharma, and Portola."
It's hard to believe that many drugmakers even exist.
But There's More
When it comes to your egregious conflicts of interest that should have prevented you from ever serving at FDA, we could talk about the 23 drugmakers who funded you when you were chancellor of clinical and translational research at Duke University like the usual suspects like Johnson & Johnson, Lilly, Merck, Schering Plough and GSK. We could talk about how you "served as a director, officer, partner, employee, advisor, consultant or trustee for Genentech" according to Medscape and on the board of Portola Pharmaceuticals.
We could also talk about how you became head of medical strategy at Google parent company Alphabet Inc. (who owns the Pharma company Verily) when you left FDA earlier. And how you presided over the discredited drug trial of the blood thinner Xarelto, was linked to 1,791 deaths six months after the FDA-trusting patients took the deadly medication.
What Will You Do Now, Pharma Bro?
With your friends in high drugmaker places and stocks you clearly don't have to haunt our government again. But please, promise! you won't come back and lean on your government associates in the full throttle cronyism that has made our government a tool of industry. You have harmed enough patients who trusted the FDA.
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
